Molecular Neurobiology
February 5, 2026
Zofia Winczewska, Wiesław Jerzy Cubała, Piotr Radziwiłłowicz et al.
5 citations
Treatment-resistant depression (TRD) poses a serious challenge to psychopharmacology, as many patients do not achieve remission despite available therapies. The persistence and recurrence of the disease in the absence of response to antidepressant treatment highlight the complex and multifactorial nature of the disease, including the dysregulation of biological processes such as oxidative...
Molecular Neurobiology
June 5, 2025
Lucas C. Santos, Fernanda Dos Santos Petry, Carolina Saibro-Girardi et al.
4 citations
Stress is widely recognized as a major environmental factor contributing to the development of mood disorders. In patients with Major Depressive Disorder (MDD) and suicidal behavior, significant hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis is observed, characterized by excessive cortisol release, which in turn stimulates the production of pro-inflammatory mediators....
Molecular Neurobiology
June 4, 2025
Naser-Aldin Lashgari, Mahla Khalaji, Pouria Rana et al.
7 citations
Neurological and psychiatric disorders are considered one of the major problems of today's societies and cause many individual and social problems. Current treatments are effective, but due to their burdens, there is always an effort to introduce novel treatments. Psychedelics, a diverse group of psychoactive compounds, including LSD, psilocybin, DMT, MDMA, and ketamine, have shown potential in...
Molecular Neurobiology
May 23, 2025
Hui Bai, Shan Du, Di Qiu et al.
4 citations
Increasing evidence reveals that multiple or prolonged exposure to ketamine causes hippocampal damage and cognitive dysfunction. However, the critical mechanisms underlying ketamine-induced neurotoxicity in the developing brain remain elusive. The present study was designed to investigate the role of GPX4 in ketamine-induced pyroptosis and cognitive dysfunction in the developing rat...
Molecular Neurobiology
May 1, 2025
Rick Wilhiam de Camargo, Larissa Joaquim, Richard Simon Machado et al.
13 citations
The psychoactive decoction Ayahuasca (AYA) used for therapeutic and religious purposes by indigenous groups and peoples from Amazonian regions produces anti-inflammatory and neuroprotective effects. Thus, it may be useful to attenuate the neuroinflammation and related anxiety- and depressive-like symptoms elicited by inflammatory insults such as sepsis. Rats were pretreated for 3 days with...
Molecular Neurobiology
March 20, 2025
Hui Bai, Hui Chen, Shan Du et al.
4 citations
Ketamine, an N-methyl-D-aspartate receptor antagonist with anesthetic and analgesic properties, is extensively utilized for the induction and maintenance of pediatric perioperative anesthesia. Increasing evidence suggests that prolonged exposure to ketamine may induce neurotoxicity in developing animals, adversely affecting their long-term cognitive function. N-acetylcysteine (NAC) is an...
Molecular Neurobiology
February 24, 2025
Zhe Du, Xiu-Mei Zhu, Peng Lv et al.
2 citations
Psychotic disorder is a significant consequence of ketamine abuse. However, the molecular mechanisms and biomarkers for this psychotic disorder and associated long-term cognitive impairment remain unclear. To investigate the behavioral changes and comprehensive gene expression alterations in mice following ketamine administration, we employed behavioral testing and RNA sequencing (RNA-seq). We...
Molecular Neurobiology
February 1, 2025
Na Hu, Yujie Zheng, Xueru Liu et al.
7 citations
The abundant expression of circular RNAs (circRNAs) in the central nervous system and their contribution to the pathogenesis of depression suggest that circRNAs are promising therapeutic targets for depression. This study explored the role and mechanism of circKat6b in esketamine's antidepressant effect. We found that intravenous administration of esketamine (5 mg/kg) treatment decreased the...
Molecular Neurobiology
November 1, 2024
Adam M Lee, Paul Thuras, Joshua Baller et al.
9 citations
Meditation-based interventions are novel and effective non-pharmacologic treatments for veterans with PTSD. We examined relationships between treatment response, early life trauma exposure, DNA polymorphisms, and methylation in the serotonin transporter (SLC6A4) and FK506-binding protein 5 (FKBP5) genes. DNA samples and clinical outcomes were examined in 72 veterans with PTSD who received...
Molecular Neurobiology
September 1, 2024
Jennifer A Cale, Ethan J Chauhan, Joshua J Cleaver et al.
8 citations
The pathogenesis of schizophrenia begins in early neurodevelopment and leads to excitatory-inhibitory imbalance. It is therefore essential that preclinical models used to understand disease, select drug targets and evaluate novel therapeutics encompass similar neurochemical deficits. One approach to improved preclinical modelling incorporates dual-hit neurodevelopmental insults, like neonatal...
Molecular Neurobiology
January 15, 2024
Yuxin Wen, Jiawen Xu, Jiahong Shen et al.
57 citations
Postoperative depression (POD) and postoperative cognitive dysfunction (POCD) have placed heavy burden on patients’ physical and mental health in recent years. Sleep disturbance before surgery is a common phenomenon that has been increasingly believed to affect patients’ recovery, especially in aged patients, while little attention has been paid to sleep disruption before surgery and the...
Molecular Neurobiology
June 1, 2019
Samuel Kohtala, Wiebke Theilmann, Marko Rosenholm et al.
Rapid antidepressant effects of ketamine become most evident when its psychotomimetic effects subside, but the neurobiological basis of this "lag" remains unclear. Laughing gas (N2O), another NMDA-R (N-methyl-D-aspartate receptor) blocker, has been reported to bring antidepressant effects rapidly upon drug discontinuation. We took advantage of the exceptional pharmacokinetic properties of N2O...
Molecular Neurobiology
June 1, 2009
João Paulo Capela, Helena Carmo, Fernando Remião et al.
“Ecstasy” [(±)-3,4-methylenedioxymethamphetamine, MDMA, XTC, X, E] is a psychoactive recreational hallucinogenic substance and a major worldwide drug of abuse. Several reports raised the concern that MDMA has the ability to induce neurotoxic effects both in laboratory animals and humans. Despite more than two decades of research, the mechanisms by which MDMA is neurotoxic are still to be fully...